[Insert Table 1]
The outcome measures were the risk of mortality and severe/critical
disease among patients with and without exposure to ACE inhibitors/ARBs
from individual studies. The pooled relative risk (and 95% confidence
interval [CI]) of mortality among patients exposed or unexposed to
ACEIs/ARBs were calculated using the random-effects model. We also
presented the absolute risk difference (reduction) and the number needed
to treat to benefit with regards to the exposure to ACEIs/ARBs.